Lilly’s Ebglyss Ok’D by FDA for Atopic Dermatitis

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) was approved by the FDA for adults and children 12 and older with moderate-to-severe atopic dermatitis, the company said.

• Patients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks
• Delivers long-lasting efficacy for patients through one year of treatment with a monthly maintenance dose

To view the source of this information, click here

To contact the reporter on this story:
Allegra Fradkin in New York at afradkin@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming at zfleming2@bloomberg.net

© 2024 Bloomberg L.P. All ...